Dexcom said that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System has been cleared by the US Food and Drug Administration (FDA) to be used in people with all types of diabetes, aged two years and older.
The diabetes management firm is said to have reduced the size of the wearable device by 60% compared to its previous generation, the G6. Dexcom G7 also has fewer components and offers a 30-minute sensor warmup time.
According to Dexcom, the continuous glucose monitoring system also features a 12-hour grace period for replacing finished sensors for a more smoother transition between sessions. It is said to offer a redesigned and streamlined mobile app with Dexcom Clarity integration, while having more improved alert settings for enhanced discretion.
The wearable has a new smaller optional receiver combined with an easier-to-read display, the diabetes management firm said. Customers aged two and older can wear it on the back of the upper arm and those between two and 17 can wear it on the upper buttocks.
Dexcom said that the device also borrows some features from the previous-generation G6. It includes no fingersticks, scanning or calibration, and real-time glucose readings that are automatically sent every five minutes. It easily integrates with connected CGM ecosystems like Apple Watch, Garmin, and other digital health apps.
The US-based diabetes management firm claimed that the G7 is the only CGM to offer a predictive low alert for early detection of potentially dangerous hypo-incidences. With a remote monitoring feature, users can share the glucose data with up to 10 followers.
Dexcom president and CEO Kevin Sayer said: “There’s a reason Dexcom has the best-selling real-time CGM on the market.
“For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability and a simpler user experience, giving people greater control of their diabetes.
“When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise.
Dexcom is planning to start a US launch of Dexcom G7 early next year.
